prostate-cancer

Simple blood test combining inflammation and nutrition markers predicts survival in metastatic prostate cancer.

The CALLY index (derived from CRP, albumin, lymphocyte count—all from routine blood tests) was tested in 192 mHSPC patients. High CALLY patients had 71% lower all-cause mortality risk (HR 0.29) and 49% lower CRPC progression risk (HR 0.51), consistent across subgroups.

Dan Manning

Dan Manning

— 1 min read
Share
Simple blood test combining inflammation and nutrition markers predicts survival in metastatic prostate cancer.

Simple blood test combining inflammation and nutrition markers predicts survival in metastatic prostate cancer.

The CALLY index (derived from CRP, albumin, lymphocyte count—all from routine blood tests) was tested in 192 mHSPC patients. High CALLY patients had 71% lower all-cause mortality risk (HR 0.29) and 49% lower CRPC progression risk (HR 0.51), consistent across subgroups.

Key Findings

  • High CALLY: 71% lower all-cause mortality (HR 0.29) in mHSPC
  • High CALLY: 49% lower risk of CRPC progression (HR 0.51)
  • Calculated from standard blood tests at no additional cost
  • Results consistent across all prespecified subgroups

Implications

CALLY could support risk stratification in mHSPC; high-risk patients could be targeted for intensified treatment.

Caveats

Retrospective single-center (n=192); abstract-only. Optimal cutoff needs independent validation.

Source: World journal of urology — 2026-04-11

Read more